Pfizer Is Trading at Less Than 10 Times Earnings. But Is the Stock Actually Cheap?

insidermonkey.com · 2026-10-11

Pfizer Inc. (NYSE:PFE) has barely rewarded shareholders over the past year. That underperformance has left Pfizer looking inexpensive.

TickrTrends take: Pfizer's forward price-to-earnings ratio below 10 represents a historically low multiple for the company, yet TickrTrends' current assessment classifies the stock as overvalued based on its broader valuation analysis. This divergence between the low earnings multiple and the overvalued rating suggests that other valuation metrics or fundamental factors may be presenting concerns that offset the apparent cheapness of the P/E ratio alone. Investors focused on valuation should monitor whether the company's earnings growth trajectory, cash flow generation, or balance sheet metrics justify the premium implied by the overvalued designation despite the single-digit earnings multiple.

Read the full story at insidermonkey.com →